Artigo Revisado por pares

Insulin infusion increases levels of free IGF-I and IGFBP-3 proteolytic activity in patients after surgery

2001; American Physiological Society; Volume: 281; Issue: 4 Linguagem: Inglês

10.1152/ajpendo.2001.281.4.e736

ISSN

1522-1555

Autores

Jonas Nygren, Christine Carlsson‐Skwirut, Kerstin Brismar, Anders Thorell, Olle Ljungqvist, P. Bang,

Tópico(s)

Cancer, Hypoxia, and Metabolism

Resumo

We have studied the effects of insulin on the bioavailability of insulin-like growth factor (IGF) I in insulin-resistant patients after surgery. Serum levels of total IGF-I (tIGF-I), free IGF (fIGF)-I, fIGF-II, and IGF-binding protein (IGFBP) 1 and IGFBP-3 proteolytic activity (IGFBP-3-PA), determined on the day before surgery and on the 1st postoperative day, were related to insulin sensitivity measured by a hyperinsulinemic, normoglycemic clamp. Before surgery, the decreased tIGF-I ( P < 0.05) in response to insulin infusion was accompanied by an 18% reduction of IGFBP-1 ( P < 0.001), while IGFBP-3-PA remained unchanged. Levels of fIGF-I and fIGF-II were not changed by insulin infusions. After surgery, IGFBP-3-PA increased ( P < 0.05) during insulin infusion, and this was associated with an increase in tIGF-I ( P < 0.001) and fIGF-I ( P < 0.01), while no significant change was found in fIGF-II. The reduction in IGFBP-1 in response to insulin infusion was not affected by surgery. The change in IGFBP-3-PA during insulin infusion after surgery was related to the corresponding change in fIGF-I ( r 2 = 0.26, P < 0.05) and postoperative insulin sensitivity ( r 2 = −0.22, P < 0.05). These data suggest that increased IGFBP-3-PA during insulin infusion after surgery governs the increased levels of fIGF-I, while insulin-induced suppression of IGFBP-1 was not affected by surgery. We propose that, in catabolic, postoperative patients, increased levels of insulin from exogenous or, possibly, endogenous sources (nutritionally induced) may be a signal to increase IGF-I bioavailability by increased expression of IGFBP-3-PA to counteract further deterioration in glucose metabolism.

Referência(s)